Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning

Turanli, BESTE; Zhang, C; Kim, W; Benfeitas, R; Uhlen, M; Arga, KAZIM; Mardinoglu, A

doi:10.1016/j.ebiom.2019.03.009

Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning

Turanli B., Zhang C., Kim W., Benfeitas R., Uhlen M., Arga K. Y., ...Daha Fazla

EBIOMEDICINE, cilt.42, ss.386-396, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 42
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.ebiom.2019.03.009
Dergi Adı: EBIOMEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.386-396
Anahtar Kelimeler: Genome-scale metabolic models, Drug repositioning, Drug repurposing, Prostate cancer, Approved drugs, LIPID-METABOLISM, PERIPHERAL ZONE, NMDA RECEPTORS, EXPRESSION, GROWTH, CELLS, ACID, TARGET, GENES
Marmara Üniversitesi Adresli: Evet

Özet

Background: Genome-scale metabolic models (GEMs) offer insights into cancer metabolism and have been used to identify potential biomarkers and drug targets. Drug repositioning is a time-and cost-effective method of drug discovery that can be applied together with GEMs for effective cancer treatment.